Clinical Trial Update: A Study to Evaluate the Safety and Dosimetry of 68Ga-labelled OncoFAP Derivatives in Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 study evaluating the safety and dosimetry of gallium-68 labelled OncoFAP derivatives in solid tumors has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Colorectal Cancer
• Esophageal Cancer
• Pancreatic Cancer

Drugs mentioned

• 68Ga-OncoFAP (gallium-68 labelled OncoFAP derivative)

Snippet

Sponsor: Philogen S.p.A. | Conditions: Breast Cancer, Colorectal Cancer | Phase 1 | Status: COMPLETED